{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:32:51Z","timestamp":1792650771837,"version":"4.5.0"},"reference-count":82,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2022,7,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In advanced Parkinson\u2019s disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet need.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To analyze changes in dyskinesia and non-motor symptoms (including sleep) among studies with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature review identified relevant studies examining LCIG efficacy. Outcomes of interest were dyskinesia (UDysRS, UPDRS IV item 32), overall non-motor symptoms (NMSS), mentation\/behavior\/mood (UPDRS I), and sleep\/daytime sleepiness (PDSS-2, ESS). The pooled mean (95% confidence interval) change from baseline per outcome was estimated for each 3-month interval with sufficient data (i.e., reported by\u22653 studies) up to 24 months using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventeen open-label studies evaluating 1243 patients with advanced PD were included. All outcomes of interest with sufficient data for meta-analysis showed statistically significant improvement within 6 months of starting LCIG. There were statistically significant improvements in dyskinesia duration as measured by UPDRS IV item 32 at 6 months (\u20131.10 [\u20131.69, \u20130.51] h\/day) and 12 months (\u20131.35 [\u20132.07, \u20130.62] h\/day). There were statistically and clinically significant improvements in non-motor symptoms as measured by NMSS scores at 3 months (\u201328.71 [\u201340.26, \u201317.15] points). Significant reduction of NMSS burden was maintained through 24 months (\u201317.61 [\u201321.52, \u201313.70] points). UPDRS I scores significantly improved at 3 months (\u20130.39 [\u20130.55, \u20130.22] points). Clinically significant improvements in PDSS-2 and ESS scores were observed at 6 and 12 months in individual studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jpd-223295","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:01:32Z","timestamp":1660302092000},"page":"2071-2083","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up"],"prefix":"10.1177","volume":"12","author":[{"given":"K. Ray","family":"Chaudhuri","sequence":"first","affiliation":[{"name":"Parkinson Foundation Centre of Excellence, King\u2019s College Hospital and King\u2019s College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[{"name":"Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration CESNE, Department of Neuroscience, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"University of Lund, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Titova","sequence":"additional","affiliation":[{"name":"N.I. Pirogov Russian National Research Medical University, Moscow, Russia"},{"name":"Federal State Budgetary Institution \u00abFederal center of brain research and neurotechnologies\u00bb of the Federal Medical Biological Agency, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Hoag Hospital Newport Beach, Newport Beach, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya J.","family":"Snedecor","sequence":"additional","affiliation":[{"name":"OPEN Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saket","family":"Hegde","sequence":"additional","affiliation":[{"name":"OPEN Health, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"},{"name":"University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Zadikoff","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27340"},{"key":"ref002","unstructured":"CoelhoM, FerreiraJJ (2017) The natural history of Parkinson\u2019s disease. In Movement Disorders Curricula, Falup-Pecurariu C, Ferreira J, Martinez-Martin P, Chaud- huri KR, eds. Springer Vienna, Vienna, pp. 129\u2013137."},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0091-2"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616681280"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00782-w"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12526"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9439-1"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-0981-5"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2016.23"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01014-4"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1159\/000131893"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.06.001"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2012-120103"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.054759"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.3.408"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13847"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12950"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.03.009"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.012"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26528"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22596"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.02.001"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.09.018"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2020-0021"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27626"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26067"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0336-5"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c0d416"},{"key":"ref033","first-page":"970534","volume":"2015","author":"Horv\u00e1th K","year":"2015","journal-title":"Parkinsons Dis"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.758"},{"key":"ref035","unstructured":"AbbVie Inc., A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson\u2019s Disease (PD) (NCT02549092), 2021https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02549092."},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afj087"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.07.021"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00351-x"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183146.78892.3f"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8951-3"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8816-9"},{"key":"ref043","first-page":"9106026","volume":"2020","author":"Gomez-Inhiesto E","year":"2020","journal-title":"Parkinsons Dis"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S160843"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27579"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0117-1"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3252-2"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb01512.x"},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.11.008"},{"key":"ref050","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.05.014"},{"key":"ref051","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26903"},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13068"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.030"},{"key":"ref054","first-page":"79","volume":"16","author":"Fasano A","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref055","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00934"},{"key":"ref056","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6798-6"},{"key":"ref057","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12630"},{"key":"ref058","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160771"},{"key":"ref059","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27027"},{"key":"ref060","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.07.020"},{"key":"ref061","unstructured":"AbbVie Inc. Data on File. Clinical Study Report: DUOGLOBE,"},{"key":"ref062","unstructured":"AbbVie Inc. Data on File. Clinical Study Report: DYSCOVER,"},{"key":"ref063","first-page":"867","volume":"35","author":"Alvarez EF","year":"2020","journal-title":"Mov Disord"},{"key":"ref064","unstructured":"AbbVie Inc. Data on File. Clinical Study Report: GLORIA,"},{"key":"ref065","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7235-1"},{"key":"ref066","unstructured":"AbbVie Inc., Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson\u2019s Disease (NCT00335153),2015, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00335153."},{"key":"ref067","unstructured":"Abbot Laboratories, Data on File. Clinical Study Report: An Open-Label, 12-Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson\u2019s Disease and Severe Motor Fluctuations Despite Optimized Treatment with Available Parkinson\u2019s Disease Medications. (2012)."},{"key":"ref068","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26123"},{"key":"ref069","unstructured":"AbbVie Inc. Data on File. Clinical study report: MONOTREAT,"},{"key":"ref070","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0571-2"},{"key":"ref071","unstructured":"Abbott Laboratories, Data on File. Clinical Study Report: A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety, and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson\u2019s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations. (2012)."},{"key":"ref072","unstructured":"AbbVie Inc., Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson\u2019s Subjects (NCT00660387), 2015, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00660387."},{"key":"ref073","unstructured":"AbbVie Inc., Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson\u2019s Subjects (NCT00357994), 2015, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00357994."},{"key":"ref074","unstructured":"Abbott Products AG, Data on File. Clinical Study Report: A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa\u00ae) in Routine Care for Subjects with Advanced Idiopathic Parkinson\u2019s Disease with Severe motor Fluctuations and Hyper-\/dyskinesiaDAPHNE(Duodopa in Advanced Parkinson\u2019s: Health outcomes&Net Economic impact), (2012)."},{"key":"ref075","unstructured":"Solvay Pharmaceuticals GmbH, Clinical Trial Results: A long-term health economics study of intraduodenal levodopa (Duodopa\u00ae) in routine care for patients with advanced idiopathic Parkinson\u2019s disease with severe motor fluctuations and hyper-\/dyskinesia. (EudraCT 2005- 002654-21). 2016. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-002654-21\/results."},{"key":"ref076","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.06.002"},{"key":"ref077","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182613dea"},{"key":"ref078","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-1153-3"},{"key":"ref079","unstructured":"AbbVie Inc., Safety\/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson\u2019s Subjects (NCT00360568), 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00360568."},{"key":"ref080","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-140456"},{"key":"ref081","unstructured":"AbbVie Inc., Data on File. Clinical Study Report: M12-920."},{"key":"ref082","unstructured":"AbbVie Inc., A Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson\u2019s Disease (NCT01736176), 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01736176."}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-223295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-223295","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-223295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:51:58Z","timestamp":1777611118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-223295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,12]]}},"alternative-id":["10.3233\/JPD-223295"],"URL":"https:\/\/doi.org\/10.3233\/jpd-223295","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}